Overview

• U.S. imports of semaglutide fell 90% from a year earlier by mid-2025 and tirzepatide dropped 34%, reflecting a sharp pullback in raw-ingredient shipments.
• At least eight Chinese firms, including Jiangsu Sinopep-Allsino and Hybio, previously supplied semaglutide and tirzepatide that enabled more than a billion makeshift doses sold online in the U.S.
• Hybio and Sinopep are reported to be developing generic semaglutide, with former suppliers such as Nanjing Hanxin and Fujian Genohope also viewed as possible entrants.
• Manufacturing the finished injectable form remains complex, and potential arrangements with branded drugmakers could slow generic launches.
• Suppliers are targeting markets such as Canada and Brazil where key semaglutide patents expire next year, as U.S. rules now limit compounding to personalized or nonstandard formulations and the FDA maintains close oversight.